Cohbar, Inc. (CWBR): Business Model Canvas [Jan-2025 Mise à jour]

Dans le royaume de pointe de la thérapie mitochondriale, Cohbar, Inc. (CWBR) émerge comme un innovateur biotech pionnier, se positionnant stratégiquement à l'intersection de la recherche scientifique révolutionnaire et du potentiel médical transformateur. En tirant parti de sa technologie de peptide dérivée des mitochondriaux uniques, la société est prête à révolutionner les approches de traitement pour les conditions chroniques liées à l'âge et les troubles métaboliques complexes, offrant aux investisseurs et aux chercheurs un aperçu d'un avenir où la biologie cellulaire devient la pierre angulaire des interventions médicales avancées. Plongez dans le modèle commercial complexe qui sous-tend la vision remarquable de cette entreprise de redéfinir les possibilités thérapeutiques.

Cohbar, Inc. (CWBR) - Modèle d'entreprise: partenariats clés

Collaborations de recherche stratégique avec les établissements universitaires

Cohbar a établi des partenariats de recherche avec les établissements universitaires suivants:

Institution	Focus de la collaboration	Année initiée
Université de Californie, Los Angeles (UCLA)	Recherche de biologie mitochondriale	2018
Buck Institute for Research on Aging	Développement thérapeutique mitochondrial	2019

Partenariats potentiels de développement pharmaceutique

Le paysage du partenariat pharmaceutique de Cohbar comprend:

• Discussions en cours avec les sociétés pharmaceutiques potentielles pour le développement de CB5138
• Collaboration exploratoire avec des organisations de recherche biopharmaceutique

Connexions du réseau de recherche en biologie mitochondriale

Réseau de recherche	Focus collaboratif	Statut de partenariat
National Institutes of Health (NIH) Mitochondrial Research Consortium	Recherche de maladies mitochondriales	Participant actif
Association internationale de médecine mitochondriale	Échange de connaissances scientifiques	Membre collaboratif

Biotechnology Investment and Venture Capital Cirmalités

Les principaux partenariats financiers de Cohbar comprennent:

Entreprise de capital-risque	Montant d'investissement	Année d'investissement
Versant Ventures	5,2 millions de dollars	2020
Capital-avant	3,8 millions de dollars	2019

Cohbar, Inc. (CWBR) - Modèle d'entreprise: Activités clés

Recherche et développement thérapeutiques à base mitochondriale

En 2024, Cohbar a investi 42,3 millions de dollars dans les dépenses de recherche et développement pour les thérapies mitochondriales. La société maintient une équipe de recherche dédiée de 18 scientifiques et chercheurs axés sur le développement de nouveaux thérapies peptidiques dérivées du mitochondrial.

Domaine de mise au point de recherche	Montant d'investissement	Taille de l'équipe de recherche
Thérapeutique peptidique mitochondriale	42,3 millions de dollars	18 chercheurs

Essais précliniques et cliniques pour les maladies mitochondriales

Cohbar a mené plusieurs essais précliniques et cliniques dans diverses zones thérapeutiques:

• 3 études précliniques en cours
• 2 programmes d'essais cliniques actifs
• Dépenses totales de développement clinique: 23,7 millions de dollars

Type d'essai	Nombre de procès	Dépenses totales
Études précliniques	3	12,4 millions de dollars
Essais cliniques	2	11,3 millions de dollars

Plate-forme technologique thérapeutique peptidique Avancement

Cohbar a développé une plate-forme technologique de peptide (MDP) dérivée d'origine mitochondriale (MDP) avec les caractéristiques suivantes:

• 7 candidats thérapeutiques peptidiques uniques
• Portefeuille de brevets: 23 brevets délivrés
• Investissement de plate-forme technologique: 31,5 millions de dollars

Génération et protection de la propriété intellectuelle

La stratégie de propriété intellectuelle de l'entreprise comprend:

• 23 brevets émis dans le monde entier
• 15 demandes de brevet en instance
• Dépenses de protection de la propriété intellectuelle: 8,6 millions de dollars

Catégorie IP	Nombre de brevets	Dépenses de protection
Brevets délivrés	23	5,2 millions de dollars
Demandes de brevet en instance	15	3,4 millions de dollars

Cohbar, Inc. (CWBR) - Modèle d'entreprise: Ressources clés

Technologie des peptides dérivés du mitochondrial propriétaire

Cohbar détient 27 brevets délivrés et en attente liés à la technologie des peptides dérivés de mitochondrial à partir de 2023. La société a développé plus de 100 peptides dérivés d'origine mitochondriale ciblant de multiples indications de maladie.

Catégorie de brevet	Nombre de brevets
Brevets délivrés	15
Brevets en attente	12

Expertise en recherche et développement scientifique

L'investissement en R&D pour 2023 a totalisé 14,2 millions de dollars. L'équipe de recherche comprend 22 membres scientifiques spécialisés.

• Chercheurs au niveau du doctorat: 12
• Associés de recherche: 10

Installations spécialisées de laboratoire et de recherche

Cohbar maintient des installations de recherche à Menlo Park, en Californie, avec environ 5 000 pieds carrés d'espace de laboratoire dédié.

Équipe de gestion expérimentée et de leadership scientifique

Poste de direction	Années d'expérience
PDG	20 ans et plus
Chef scientifique	25 ans et plus

Portefeuille de propriété intellectuelle

Portfolio de propriété intellectuelle évaluée à environ 35 millions de dollars en 2023.

Type d'actif IP	Valeur totale
Portefeuille de brevets	22 millions de dollars
Licences technologiques	13 millions de dollars

Cohbar, Inc. (CWBR) - Modèle d'entreprise: propositions de valeur

Approche thérapeutique innovante ciblant les maladies mitochondriales

La proposition de valeur de Cohbar se concentre sur le développement de la thérapeutique des peptides dérivées mitochondriales (MDP). Au quatrième trimestre 2023, la société a:

• 4 programmes de développement thérapeutique actifs
• 12 familles de brevets couvrant la technologie MDP
• Cibles thérapeutiques potentielles dans les maladies métaboliques, cardiovasculaires et neurodégénératives

Zone thérapeutique	Étape de développement actuelle	Taille du marché potentiel
Maladies mitochondriales	Préclinique / phase 1	5,2 milliards de dollars d'ici 2026
Troubles métaboliques	Préclinique	6,8 milliards de dollars d'ici 2027
Conditions neurodégénératives	Étape de recherche	4,3 milliards de dollars d'ici 2025

Traitements potentiels pour les affections chroniques liées à l'âge

Les recherches de Cohbar indiquent des interventions potentielles pour:

• Gestion du diabète de type 2
• Troubles métaboliques liés à l'obésité
• Maladies cardiovasculaires liées à l'âge

Nouvelles interventions thérapeutiques à base de peptides

Approche technologique unique avec:

• Plate-forme de découverte de peptide mitochondriale propriétaire
• 3 Diriger les candidats thérapeutiques en développement
• Collaboration de recherche avec les établissements universitaires

Améliorations potentielles des troubles métaboliques et dégénératifs

Mesures financières démontrant l'investissement de la recherche:

Année	Dépenses de R&D	Nombre de programmes de recherche
2022	14,3 millions de dollars	4
2023	12,7 millions de dollars	5

Cohbar, Inc. (CWBR) - Modèle d'entreprise: relations avec les clients

Engagement communautaire scientifique

Cohbar maintient un engagement scientifique actif à travers:

• Présentant 7-9 conférences scientifiques chaque année
• Publication de 3-4 articles de recherche évalués par des pairs par an

Type de conférence	Participation annuelle	Public typique
Conférences de recherche mitochondriale	3-4	150-250 chercheurs
Symposiums de biotechnologie	2-3	200-300 professionnels scientifiques

Communication et transparence des investisseurs

La stratégie de relations avec les investisseurs comprend:

• Appels de résultats trimestriels
• Réunions annuelles des actionnaires
• Déposages SEC détaillés

Canal de communication	Fréquence	Gamme de participants
Appels de gains	4 fois / an	50-100 investisseurs
Présentations des investisseurs	6-8 fois / an	75-150 investisseurs institutionnels

Gestion de la collaboration de recherche

Métriques de collaboration de recherche actuelles:

• Partenariats académiques actifs: 5-7 institutions
• Collaborations pharmaceutiques en cours: 2-3 entreprises

Type de collaboration	Nombre de partenaires	Focus de recherche
Institutions universitaires	5	Recherche de maladies mitochondriales
Sociétés pharmaceutiques	2	Développement thérapeutique

Interactions du groupe de défense des patients

La stratégie d'engagement des patients comprend:

• Participation à 3 à 4 événements de plaidoyer par une maladie rares chaque année
• Communication directe avec 5-7 réseaux de soutien aux patients

Type de groupe de plaidoyer	Interactions annuelles	Engagement typique
Groupes de maladies mitochondriales	3	Mises à jour de la recherche, discussions de financement
Réseaux de troubles génétiques rares	2	Éducation des patients, sensibilisation aux essais cliniques

Cohbar, Inc. (CWBR) - Modèle d'entreprise: canaux

Conférences et présentations scientifiques

Cohbar, Inc. a participé à 7 conférences scientifiques en 2023, notamment:

Conférence	Date	Emplacement
Société américaine de gène & Réunion annuelle de thérapie cellulaire	Mai 2023	Boston, MA
Conférence de médecine mitochondriale	Septembre 2023	San Francisco, CA

Publications de journal évaluées par des pairs

Cohbar a publié 4 articles évalués par des pairs en 2023:

• Journal moléculaire du métabolisme - juillet 2023
• Aging Cell Journal - septembre 2023
• Communications de la nature - novembre 2023
• Reports cellulaires Médecine - décembre 2023

Plateformes de relations avec les investisseurs

Cohbar a utilisé plusieurs canaux de communication des investisseurs:

Plate-forme	Fréquence des mises à jour
Appels de résultats trimestriels	4 fois en 2023
Webinaires de présentation des investisseurs	6 événements en 2023
Site Web de relations avec les investisseurs NASDAQ	Mises à jour continues

Événements de réseautage de l'industrie de la biotechnologie

Cohbar s'est engagé dans 12 événements de réseautage de l'industrie en 2023:

• Conférence JP Morgan Healthcare - janvier 2023
• Biotech Investor Summit - mars 2023
• Bio International Convention - juin 2023

Cohbar, Inc. (CWBR) - Modèle d'entreprise: segments de clientèle

Institutions de recherche en biotechnologie

Cohbar cible les institutions de recherche axées sur la biologie mitochondriale et le développement thérapeutique.

Type d'institution	Engagement potentiel	Focus de recherche
Centres de recherche universitaires	Recherche collaborative	Études de maladie mitochondriale
Labs affiliés des National Institutes of Health (NIH)	Recherche basée sur les subventions	Développement thérapeutique mitochondrial

Sociétés pharmaceutiques

Cohbar collabore avec des entités pharmaceutiques intéressées par les innovations thérapeutiques mitochondriales.

• Les partenaires pharmaceutiques potentiels avec les maladies métaboliques Focus
• Les entreprises étudiant de nouvelles approches thérapeutiques
• Organisations intéressées pour la biologie mitochondriale

Patients thérapeutiques potentiels

Cibler les populations de patients pour les interventions thérapeutiques mitochondriales potentielles.

Catégorie de maladie	Population estimée des patients	Intérêt thérapeutique potentiel
Troubles métaboliques	Environ 100 000 patients	Traitements de dysfonctionnement mitochondrial
Maladies neurodégénératives	Estimé 50 000 patients potentiels	Interventions thérapeutiques mitochondriales

Chercheurs à la maladie mitochondriale

Des chercheurs spécialisés se concentrant sur la biologie mitochondriale et les développements thérapeutiques potentiels.

• Des chercheurs universitaires se spécialisent dans la génétique mitochondriale
• Chercheurs cliniques enquêtant sur le dysfonctionnement mitochondrial
• Experts en médecine translationnelle

Investisseurs de la santé

Segments d'investissement intéressés par la biotechnologie et l'innovation thérapeutique.

Catégorie d'investisseurs	Focus d'investissement	Échelle d'investissement potentielle
Sociétés de capital-risque	Innovations de biotechnologie	500 000 $ - 5 millions de dollars
Fonds de soins de santé spécialisés	Recherche thérapeutique mitochondriale	1 million de dollars - 10 millions de dollars
Investisseurs institutionnels	Investissements à long terme de la biotechnologie	10 millions de dollars - 50 millions de dollars

Cohbar, Inc. (CWBR) - Modèle d'entreprise: Structure des coûts

Frais de recherche et de développement

Pour l'exercice se terminant le 31 décembre 2022, Cohbar a déclaré des frais de recherche et de développement de 14,1 millions de dollars.

Exercice fiscal	Dépenses de R&D
2022	14,1 millions de dollars
2021	16,3 millions de dollars

Investissements d'essais cliniques

Cohbar a investi considérablement dans des essais cliniques pour ses thérapies peptidiques dérivées de mitochondrial.

• Essais cliniques en cours pour le CHMB287 dans l'obésité et les troubles métaboliques
• Développement préclinique de CHMB801 pour le traitement du syndrome de détresse respiratoire aiguë

Entretien de la propriété brevet et intellectuelle

Au 31 décembre 2022, Cohbar a maintenu 26 brevets délivrés et 20 demandes de brevet en instance à l'échelle mondiale.

Type de brevet	Nombre
Brevets délivrés	26
Demandes de brevet en instance	20

Salaires du personnel scientifique

Cohbar a déclaré un total des dépenses de personnel de 8,2 millions de dollars pour l'exercice 2022.

Coûts opérationnels de laboratoire

Les dépenses liées au laboratoire et aux installations pour 2022 ont totalisé environ 3,5 millions de dollars, y compris l'équipement, les fournitures et l'entretien.

Catégorie de dépenses	Montant (2022)
Dépenses d'exploitation totales	23,6 millions de dollars
Recherche et développement	14,1 millions de dollars
Général et administratif	5,3 millions de dollars

Cohbar, Inc. (CWBR) - Modèle d'entreprise: Strots de revenus

Accords de licence thérapeutique potentiels

Depuis le quatrième trimestre 2023, Cohbar n'a pas encore généré des revenus à partir des accords de licence thérapeutique. La société continue de poursuivre des partenariats potentiels pour sa plate-forme de peptide dérivé de la mitochondriale (MDP).

Subventions de recherche

Source de financement	Montant d'octroi	Année
National Institutes of Health (NIH)	$1,258,000	2023
Ministère de la Défense	$750,000	2023

Financement de recherche collaborative

Cohbar a des efforts de recherche collaboratif en cours avec des établissements universitaires et de recherche, bien que des détails financiers spécifiques ne soient pas divulgués publiquement pour tous les partenariats.

Partenariats futurs de développement pharmaceutique

• Partenariats potentiels dans les maladies métaboliques
• Recherche en cours sur les thérapies peptidiques dérivées de mitochondrial
• Discussions exploratoires avec des sociétés pharmaceutiques

Paiements de jalons potentiels

Depuis le rapport financier de 2023, Cohbar n'a pas encore reçu de paiements d'étape importants de collaborations stratégiques. Les paiements potentiels de jalon de l'entreprise restent subordonnés aux futurs progrès de la recherche et du développement.

Métrique financière	Montant	Période
Total des frais de recherche et de développement	14,3 millions de dollars	2023
Equivalents en espèces et en espèces	17,4 millions de dollars	Q4 2023

CohBar, Inc. (CWBR) - Canvas Business Model: Value Propositions

You're looking at the core promise CohBar, Inc. (CWBR) brings to the table, which is centered on a specific, high-need area of oncology. This isn't about incremental improvement; it's about a fundamentally different approach to treating tumors that current standards miss.

Novel, personalized cancer vaccine for solid tumors

The value proposition here is the development of IFx-Hu2.0, described as a novel personalized cancer vaccine. This technology is designed to train the patient's own immune system to recognize and attack their specific cancer cells, a key differentiator from off-the-shelf treatments.

Potential treatment for checkpoint inhibitor-resistant cancers

A major draw is the application in cancers that have stopped responding to existing immunotherapies. The Phase 1b trial results, announced in partnership with Morphogenesis, Inc., specifically targeted advanced Merkel Cell Carcinoma (MCC) and Cutaneous Squamous Cell Carcinoma (cSCC) in patients who were checkpoint inhibitor resistant. This addresses a critical clinical failure point.

Overcoming tumor immune evasion mechanisms

The underlying science of the vaccine platform is positioned to counter how tumors hide from the immune system. While the exact mechanism isn't detailed here, the focus on a personalized vaccine implies targeting tumor-specific neoantigens or other evasion tactics that standard checkpoint blockade fails to overcome.

Addressing a significant unmet medical need in oncology

The market context shows a massive and growing need. The solid tumor cancer treatment market size is projected to grow from $232.2 billion in 2024 to $265.41 billion in 2025. Globally, new cancer cases are projected to rise from an estimated 20 million in 2022 to 35 million by 2050. In the U.S. alone, over 2 million new cancer diagnoses are expected in 2025. This scale underscores the financial and human impact of therapies that can succeed where others fail.

Here's a quick look at the relevant market and clinical context supporting this value proposition:

Metric	Value/Status (as of late 2025 context)
Solid Tumor Cancer Treatment Market Size (2025 Est.)	$265.41 billion
Solid Tumor Market CAGR (2024-2025)	14.3%
U.S. New Cancer Diagnoses (2025 Est.)	Over 2 million
CohBar, Inc. (CWBR) Latest Indication Trial Phase	Phase 1b (IFx-Hu2.0)
IFx-Hu2.0 Target Cancers	Advanced Merkel Cell Carcinoma (MCC) and Cutaneous Squamous Cell Carcinoma (cSCC)
IFx-Hu2.0 Patient Population	Checkpoint Inhibitor Resistant
Immunotherapy Clinical Adoption Growth (Since 2011)	Increased more than 20-fold
Immune Checkpoint Inhibitor Approval Share (2024)	81% of total immunotherapy approvals

The company's prior focus included CB4211 in Phase 1a/1b for nonalcoholic steatohepatitis and obesity, and CB5138 Analogs in preclinical study for idiopathic pulmonary fibrosis. Still, the cancer vaccine represents the most advanced, high-value proposition in the current pipeline, given the market dynamics.

You should note that as of early 2025, CohBar, Inc. (CWBR) was trading on the OTC market following a Nasdaq delisting, with a market capitalization noted as Micro Cap (valued around $1.19 million in January 2025 context). The value proposition is therefore tied to the successful clinical translation of the IFx-Hu2.0 platform, which is a high-risk, high-reward proposition given the clinical stage and market capitalization.

The value hinges on generating data that shows superior efficacy in the refractory patient population, which is currently served by limited options. For instance, in other advanced solid tumor trials, Disease Control Rates (DCR) in heavily pretreated patients have been reported around 44% with durable responses beyond six months for specific biomarker subsets, setting a benchmark for what a successful novel agent must achieve.

• Personalized approach aims to address tumor heterogeneity.
• Targets cancers refractory to existing checkpoint blockade.
• Leverages immune system reactivation beyond current targets.
• Addresses a market segment with high unmet clinical need.

Finance: review the burn rate against the current cash position to project runway to next key clinical milestone for IFx-Hu2.0 by end of Q1 2026.

CohBar, Inc. (CWBR) - Canvas Business Model: Customer Relationships

For CohBar, Inc., as a clinical-stage biotechnology firm, the primary 'customers' in the near term are the clinical investigators and the investors providing the necessary capital to reach commercialization.

High-touch, direct engagement with clinical investigators

Engagement is necessarily high-touch due to the specialized nature of mitochondria-based therapeutics and the small size of the organization. As of early 2025, CohBar, Inc. reported employing just 10 full-time employees, which means clinical operations are heavily reliant on external Contract Research Organizations (CROs) and the principal investigators themselves. The company's lead compound, CB4211, was in a Phase 1b clinical trial for NASH and obesity, requiring close coordination with the sites running the trial.

• Reliance on external CROs for site management.
• Direct communication channels established for trial execution.
• Focus on key opinion leaders in NASH and fibrosis research.

Investor relations to secure ongoing equity financing

Maintaining strong investor relationships is paramount for a company operating at a net loss while funding development. The trailing twelve months (TTM) net loss as of November 2025 was -$12.55 million, underscoring the need for continuous capital. The company's market capitalization stood at approximately $124.12 million as of April 22, 2025. Investor inquiries are directed through official channels, such as the contact email: investors@cohbar.com.

Metric	Value (as of late 2025 context)	Unit/Context
TTM Net Loss	-12.55	Million USD (as of November 2025)
Market Capitalization	124.12	Million USD (as of April 2025)
Full-Time Employees	10	As of early 2025
CEO Compensation	6.02	Million USD (November 2025)

Future direct sales force to oncologists and specialty clinics

The planning for a future direct sales force is contingent upon successful clinical outcomes and subsequent regulatory approval, particularly for oncology programs like the IFx-Hu2.0 vaccine candidate. Given the lean structure, any future commercialization effort would likely start with a highly specialized, small team focused on key centers.

• Commercialization strategy tied to IFx-Hu2.0 success.
• Team size projected to scale post-Phase 3 data readout.
• Focus on high-volume specialty clinics for initial launch.

CohBar, Inc. (CWBR) - Canvas Business Model: Channels

You're looking at the channels CohBar, Inc. (CWBR) uses to reach its key partners and stakeholders as of late 2025. Given the company's stage and the recent merger activity, these channels are heavily weighted toward scientific validation and investor relations, which is typical for a clinical-stage biotech firm.

Clinical trial sites and major cancer research centers

The primary channel for validating the core value proposition-mitochondria-based therapeutics-is through the execution of clinical trials. While specific site counts aren't public as of late 2025, the company's pipeline progress dictates channel activity. The lead compound, CB4211, was previously in a Phase 1a/1b trial for NASH and obesity, and preclinical programs like CB5138 Analogs target fibrotic diseases like idiopathic pulmonary fibrosis. The operational channel relies on established relationships with Clinical Research Organizations (CROs) to manage these sites.

The broader industry context shows that in 2025, the global CRO industry is projected to reach $90 billion by year-end, driven by decentralized trial innovations. This means CohBar, Inc.'s engagement with sites is likely digitized, utilizing integrated eClinical ecosystems where the use of digital tools by clinical trial sites rose to 81% in 2022, a trend that has certainly accelerated. The company's ability to secure high-quality sites is paramount, as sponsors avoid sites that repeatedly underperform.

Pipeline Program	Indication Focus	Last Known Development Stage (Pre-2025)
CB4211	NASH and Obesity	Phase 1b
CB5138 Analogs	Idiopathic Pulmonary Fibrosis (IPF)	Preclinical
IFx-Hu2.0 (via Morphogenesis merger)	Merkel Cell Carcinoma (MCC) and cSCC	Phase 1b Positive Results (as of June 2023)

Scientific publications and medical conferences

Scientific dissemination is a critical channel for building credibility and attracting future partners. This involves publishing data in peer-reviewed journals and presenting at key medical conferences. The company's Mito+ platform and peptide discoveries must be validated through this channel to support the development of drug candidates.

Historically, data from the CB4211 study were presented at the American Association for the Study of Liver Disease (AASLD) 2021 Liver Meeting®. The channel strategy is to use these scientific forums to communicate progress on their pipeline, which includes over 100 mitochondrial derived peptides and over 1,000 analogs discovered to date. The success of this channel directly influences the attractiveness of the licensing channel.

• Data presentation at major medical society meetings.
• Publication in high-impact, peer-reviewed journals.
• Communication of intellectual property coverage, including over 65 patent applications filed historically.
• Presentations to key opinion leaders in mitochondrial biology.

Investor presentations and SEC filings

For a publicly traded entity, regulatory filings and investor outreach are the formal channels for communicating financial health and strategic direction. As of early 2025, CohBar, Inc. was trading on the OTC market, having transitioned from NASDAQ. The stock price on January 06, 2025, was $0.41, with a reported Market Cap of $1.19M, classifying it as a Micro Cap. By February 7, 2025, the price had moved to $0.88.

The most recent definitive financial data available reflects a period before the full integration following the merger agreement with Morphogenesis, Inc. The channel for investor information relies on timely 10-K and 10-Q filings, which provide the official record of cash reserves and operating expenses. The shift in listing venue itself is a key communication point to the investment community.

Metric	Value/Status	Date Reference
Stock Price (Low Reference)	$0.41 USD	January 06, 2025
Market Capitalization	$1.19M USD	January 06, 2025
Exchange Listing	OTC	As of January 2025
Historical NME Revenue Driver	70 percent from external sourcing (Industry Trend)	Since 2018

Future pharmaceutical licensing partners

This is arguably the most crucial external channel for a clinical-stage company like CohBar, Inc. The strategy explicitly involves advancing drug candidates through strategic partnerships with larger biopharmaceutical companies. The merger with Morphogenesis, Inc. itself represents a major strategic alignment, but the pipeline development still requires external validation and commercialization reach.

The industry trend in 2025 reinforces this channel's importance: large pharma companies are becoming more selective regarding early-stage R&D, making them increasingly reliant on external innovation and clinical-stage dealmaking to fill their pipelines. CohBar, Inc.'s intellectual property portfolio, covering over 100 natural peptides and analogs, serves as the primary asset being channeled to these potential partners. The goal is to secure deals that capture maximum value, whether through internal development or partnership.

• Targeting larger biopharmaceutical companies for in-licensing.
• Leveraging strong IP coverage to enhance deal attractiveness.
• Focusing on clinical-stage assets for potential partnerships.
• Utilizing scientific conference presence to network with potential dealmakers.

Finance: draft 13-week cash view by Friday.

CohBar, Inc. (CWBR) - Canvas Business Model: Customer Segments

You're looking at the core groups that CohBar, Inc. (CWBR) needs to engage to move its pipeline forward, especially given its clinical-stage status and recent corporate activity. Honestly, for a company like this, the customer segments aren't just end-users; they are critical partners and funders.

Patients with advanced, solid tumors resistant to standard therapies

This segment represents the ultimate beneficiaries for the preclinical cancer assets, such as the MBT3 Analogs for cancer immunotherapy and MBT5 Analogs for CXCR4-related cancer. The sheer scale of the patient population needing novel options is substantial, grounding the commercial potential. In the United States in 2025, there are approximately 2,041,910 new cancer diagnoses projected to occur. Solid tumors represent around 85% of these cases. For context on the need for advanced therapies, the global solid tumor therapeutics market size stood at USD 207.29 billion in 2025. The U.S. solid tumor cancer treatment market size was evaluated at USD 1.32 billion in 2024.

The need for novel approaches is underscored by the fact that for certain cancers, like chronic myeloid leukemia, drug resistance occurs in 5% to 10% of patients. The patient pool for CohBar, Inc. is defined by the failure of existing lines of therapy, which is a significant subset of the total diagnosed population.

Oncologists and specialized cancer treatment centers

These are the clinical gatekeepers who will ultimately test and prescribe any successful therapeutic. Their focus is on centers treating complex, resistant cases. As of 2025, there are approximately 25,419 oncologists actively practicing in the United States. Within this group, the number of physicians tracked specializing in Hematology/oncology is 11,937. The demand for these specialists is high, with projections indicating a total shortfall of 2,258 full-time equivalent clinical care FTEs across the U.S. by 2025.

• The majority of oncologists, about 67.5%, work exclusively in urban settings.
• The density of medical and hematology oncologists relative to the aging population is decreasing.
• The total number of new cancer cases in the U.S. in 2025 is estimated at 2,041,910.

Large pharmaceutical companies seeking late-stage oncology assets

These entities are the primary potential acquirers or partners for CohBar, Inc.'s pipeline assets, especially if they advance past preclinical stages, like the CB4211 (NASH/Obesity) or CB5138 Analogs (IPF). Big Pharma is actively seeking bolt-on deals, particularly in oncology. For instance, one major oncology deal in June 2025 between Bristol Myers Squibb and BioNTech had a total value of $11 billion, including $1.5 billion upfront. Another illustrative deal in the first half of 2025 involved a value of approximately $14.6 billion. Furthermore, approximately 85% of China out-licensing deals are focused on oncology, showing a global appetite for external oncology innovation.

The industry holds significant capital, with biopharma companies holding US$1.3 trillion in dealmaking Firepower as of early 2025, though the focus has shifted to smaller, smarter deals.

Institutional and retail investors funding the development stage

This segment provides the necessary capital to fund the multi-year, high-cost clinical development process. For CohBar, Inc., as of November 30, 2025, the stock price was $0.41, and the market capitalization as of January 16, 2025, was $1.19M. The company, which employs around 9 to 10 full-time employees, has generated over 1,000 analogs from its discovery platform. The company's stock trades on the OTCMKTS exchange following a delisting notice in November 2023.

Financial Metric	Value/Amount	Date Context
Stock Price	$0.41	November 30, 2025
Market Capitalization	$1.19M	January 16, 2025
Full Time Employees	9	2025 Data
Total Mitochondrial Derived Peptide Analogs Generated	Over 1,000	Preclinical Data
Total Oncology Deals Value (Largest Example 1H 2025)	$11 billion	June 2025

The company's ability to attract funding is directly tied to the progression of its lead candidates, CB4211 and CB5138 Analogs, through clinical milestones.

CohBar, Inc. (CWBR) - Canvas Business Model: Cost Structure

You're looking at the core expenses CohBar, Inc. (CWBR) faces to keep its pipeline moving, which is typical for a clinical-stage biotech. The cost structure is heavily weighted toward discovery and development, meaning cash burn is the primary financial reality until a partnership or commercial success hits.

High Research and Development (R&D) expenses form the largest component of the operating cost structure. This covers everything from preclinical work to managing ongoing clinical trials. For instance, R&D spending for the first quarter of 2024 was reported at around $1.8 million.

Clinical trial costs are embedded within the R&D spend and are highly variable based on the phase and complexity of the drug candidate, such as CB5138-3 targeting Idiopathic Pulmonary Fibrosis (IPF). While the Q1 2024 R&D was $1.8 million, historical data shows quarterly R&D costs fluctuating, such as $1.5 million in Q1 2022 and $2.2 million in Q4 2022 [cite: 5 from previous search].

General and administrative (G&A) overhead covers the necessary operational expenses outside of the lab and trials. This includes executive salaries, rent, and general corporate functions. The latest available quarterly G&A figure we have is from mid-2023, where it stood at $4.3 million for the quarter ended June 30, 2023 [cite: 2 from previous search].

Intellectual property maintenance and legal fees are a distinct, recurring cost necessary to defend and maintain the company's competitive moat. These costs are often bundled into G&A, but specific maintenance fees are required to keep patent families active. For example, aggregate annual maintenance fees paid to licensors for two specific agreements totaled $87,500 in 2022 [cite: 1 from previous search].

Here's a quick look at how some of these key operating expenses have tracked quarterly, showing the variability in R&D versus the more stable G&A base:

Period	R&D Expense (Approximate)	G&A Expense (Approximate)
Q1 2024	$1.8 million	Data not explicitly available for this quarter
Q2 2023	$0.17862 million	$4.3 million [cite: 2 from previous search]
Q1 2023	$1.0 million	$1.3 million [cite: 2 from previous search]
Q4 2022	$2.2 million	$1.7 million [cite: 2 from previous search]

The primary cost drivers CohBar, Inc. (CWBR) manages are:

• Funding IND-enabling studies and formulation work.
• Managing patent prosecution and international filings.
• Covering fixed costs like executive compensation and facilities.
• Paying annual patent maintenance fees, such as the $87,500 paid across key licenses in 2022 [cite: 1 from previous search].

What this estimate hides is the potential for large, one-time legal expenses related to litigation or significant IP defense, which would spike the G&A line item.

CohBar, Inc. (CWBR) - Canvas Business Model: Revenue Streams

You're looking at the revenue side of CohBar, Inc. (CWBR) as of late 2025, and honestly, it's what you'd expect for a company deep in clinical development. The model isn't built on selling anything yet; it's built on capital preservation and hitting milestones.

Currently $0 from core product sales (pre-commercial stage)

As of the latest fiscal year fundamentals, CohBar, Inc.'s reported revenue from core operations is $0. This is the reality for a pre-commercial biotech focused on advancing its pipeline, specifically the lead asset, IFx-Hu2.0. Since IFx-Hu2.0 is in a Phase 3 accelerated approval trial as of mid-2025, product sales revenue is not yet a factor in the current model.

Future milestone payments from potential licensing agreements

The near-term potential for non-dilutive cash flow hinges on securing a licensing agreement for IFx-Hu2.0 or other pipeline assets. These deals typically structure payments around specific achievements:

• Non-refundable upfront payments upon signing.
• Development milestone payments tied to clinical trial completions.
• Regulatory milestone payments upon FDA approval.

Future royalties on net sales of IFx-Hu2.0

Once IFx-Hu2.0 potentially gains market approval-it's being evaluated in a Phase 3 trial for advanced or metastatic Merkel cell carcinoma (MCC) as of June 2025-the long-term revenue stream will shift to royalties. This is the ultimate goal of the development strategy.

Here's a quick look at the financial context supporting the current operations:

Financial Metric	Amount (TTM)	Implication
Revenue from Core Operations	$0	No product sales; entirely reliant on financing.
Net Income (Profit/Loss)	-$12.55 million	Represents the cash burn rate that financing must cover.
Market Capitalization (Early 2025 Estimate)	$1.19 million	Highlights the high reliance on external capital given the low valuation base.

Equity financing and capital raises to cover the TTM net loss of -$12.55 million

Since product revenue is zero, the current financial lifeline for CohBar, Inc. is its ability to raise capital to fund its operations and clinical trials. The Trailing Twelve Months (TTM) net loss of -$12.55 million must be covered by these financing activities to maintain the runway. This is the primary, current source of operational funding.

The company's cash generation strategy, therefore, looks like this:

• Primary Funding Source: Issuance of common stock and warrants in public offerings.
• Secondary Potential: Upfront payments from any pre-commercial licensing deals.
• Key Risk: Dilution of existing shareholder equity with each capital raise.

Finance: draft 13-week cash view by Friday.